Current Investments

---

Deal Involvement

Nina Kjellson focuses primarily on investments in the biopharmaceutical area. She is a board member of Alvine Pharmaceuticals, Nereus Pharmaceuticals, NovaCardia, Inc. and Trius Therapeutics. Additionally, she is an observer on the boards of AkaRx, Inc., Devax, Inc., Kanisa Pharmaceuticals and MacuSight, Inc. Kjellson also played a primary role in InterWest's investment in Aspreva Pharmaceuticals (Nasdaq: ASPV).

Prior to joining InterWest, Kjellson was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Kjellson began her career conducting health policy and survey research with the Kaiser Family Foundation.

Kjellson holds a B.S. in human biology from Stanford University.

A Word from Nina

"I've always known that my career would focus on medicine and the life sciences as I am committed to advancing healthcare technologies and improving access to care. At InterWest, I hope to implement an investment strategy that integrates market vision and technical innovation with sound business planning and leadership. In so doing, it is my objective to partner with the entrepreneurs and scientists working to change the face of healthcare."